What is Brooks Laboratories Ltd (BROOKS) share price return in the past 10 years?

Brooks Laboratories Ltd share price has declined -0.5% annually (CAGR) over the past ten years.

What is the share price of Brooks Laboratories Ltd (BROOKS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Brooks Laboratories Ltd (BROOKS) on 04-Jun-2026 16:59:59 at 16:59 is 63.98.

What is the P/E ratio of Brooks Laboratories?

The latest standalone P/E ratio of Brooks Laboratories as of 04-Jun-2026 is 32.47.

What is the P/B ratio of Brooks Laboratories Ltd (BROOKS)?

The latest standalone P/B ratio of Brooks Laboratories Ltd (BROOKS) as of 04-Jun-2026 is 1.56.

What is the 52-week high and low of Brooks Laboratories Ltd (BROOKS)?

The 52-week high of Brooks Laboratories Ltd (BROOKS) is Rs. 165.95 and the 52-week low is Rs. 36.90.

Brooks Laboratories Ltd (BROOKS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Brooks Laboratories Ltd (BROOKS)
Brand: Brooks Laboratories

Brooks Laboratories Ltd (BROOKS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533543 NSE: BROOKS Pharmaceuticals & Drugs | Small Cap | Brooks Laboratories Share Price

Brooks Laboratories Ltd (BROOKS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533543 NSE: BROOKS Pharmaceuticals & Drugs | Small Cap | Brooks Laboratories Share Price

Key Metrics

Valuation Multiples

Market Cap

₹188 Cr.

Current Price

₹64

52-Week Low / High

₹37 / 166

TTM EPS

₹2

TTM Sales

₹85.7 Cr.

Book Value per Share

₹41

P/E Ratio

32.47

Lower than its 3-year historical median

Industry PE

46.5

Price to Book (P/B)

1.56

Lower than its 5-year historical median

Price to Sales (P/S)

2.20

Lower than its 5-year historical median

EV/EBITDA

22.87

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

3.31%

Underperforms industry median

Return on Capital Employed (ROCE)

4.35%

Underperforms industry median

Return on Assets (ROA)

2.60%

Operating Profit Margin

1.7%

Net Profit Margin

3.7%

Gross Profit Margin

5.9%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

3.86%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-55.23%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

99.35%

Asset Quality

Promoter Holding

52.62%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹91 Cr.

Equity

₹29.5 Cr.

Face Value

₹10

All Time Low / High

₹10.32 / 202.80

Brooks Laboratories stock performance

Key Ratios

Check Before You Invest

Quality

Not Good

Check detailed performance

Valuation

Somewhat Undervalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Brooks Laboratories Ltd a good quality company?

Brooks Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Brooks Laboratories Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Brooks Laboratories Ltd vs industry peers?

Brooks Laboratories Ltd revenue CAGR is 3.45%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Brooks Laboratories Ltd?

Promoters hold 52.62% of the Brooks Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Brooks Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -1.9% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	9.7%	2.6%	-10.6%	-8.6%	-7.8%	-5.2%	1.9%	-11.2%	3.5%	4.4%	-
Value Creation Index ⓘ	-0.3	-0.8	-1.8	-1.6	-1.6	-1.4	-0.9	-1.8	-0.8	-0.7	-
Growth Parameters ⓘ
Sales ⓘ	80	57.5	55.7	55	69.7	77.3	77	55.5	79.5	82.6	86
Sales YoY Gr.	-	-28.1%	-3.2%	-1.2%	26.6%	10.9%	-0.4%	-27.8%	43.1%	3.9%	-
Adj EPS ⓘ	5.4	0.9	-7.1	-7.7	-9.4	-6.3	0.1	-3.3	0.5	1	2
YoY Gr.	-	-84.3%	-929.4%	NA	NA	NA	NA	-2435.7%	NA	85.2%	-
BVPS (₹) ⓘ	62.3	65.4	58.4	50.8	39.5	25.7	26.1	22.8	26.5	39.1	41
Adj Net Profit ⓘ	10.6	1.7	-13.8	-15.1	-23.4	-15.7	0.3	-8.2	1.4	2.9	6
Cash Flow from Ops. ⓘ	8.1	9.6	-6.2	-5.1	-9.4	-0.9	3.1	0.6	-9.8	2.6	-
Debt/CF from Ops. ⓘ	0.7	1.4	-4.5	-6.2	-2.9	-9.3	1.6	10.3	-0.5	2.3	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	0.4%	3.5%	2.4%	3.9%
Adj EPS ⓘ	-17.1%	NA	92.6%	85.2%
BVPSⓘ	-5.1%	-0.2%	14.4%	47.5%
Share Price	-0.5%	-8.8%	1.7%	-54.3%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	9.1	1.3	-11.4	-13.7	-23	-19.3	0.5	-13.4	2.2	3.2	4.9
Op. Profit Mgn % ⓘ	13.9	8.8	-16	-15.2	-3.7	1.3	2.4	-10.4	3.9	1.7	8.2
Net Profit Mgn % ⓘ	13.2	2.9	-24.8	-27.4	-33.6	-20.3	0.4	-14.7	1.8	3.6	6.8
Debt to Equity ⓘ	0.1	0.1	0.2	0.3	0.3	0.1	0.1	0.1	0.1	0.1	0
Working Cap Days ⓘ	216	227	208	234	206	168	159	226	144	150	78
Cash Conv. Cycle ⓘ	25	2	7	-7	7	34	31	29	19	52	33

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	80	58	56	55	70	77	77	56	79	83
Operating Expenses ⓘ +	69	52	65	63	74	76	75	61	76	81
Manufacturing Costs	4	3	8	6	7	8	7	4	5	6
Material Costs	53	37	39	39	47	48	49	40	57	54
Employee Cost	5	6	10	10	11	12	11	11	10	12
Other Costs ⓘ	7	6	8	8	9	9	8	6	5	9
Operating Profit ⓘ	11	5	-9	-8	-4	1	2	-6	3	1
Operating Profit Margin (%)	13.9%	8.8%	-16.0%	-15.2%	-5.6%	1.2%	2.4%	-10.5%	3.9%	1.7%
Other Income ⓘ +	2	0	0	3	0	1	1	0	1	4
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	1	1	2	3	3	3	1	1	1	1
Depreciation ⓘ	1	2	6	6	7	7	1	2	2	2
Profit Before Tax ⓘ	11	2	-18	-15	-14	-8	1	-8	2	3
Tax ⓘ	0	1	-4	-0	11	7	0	0	0	0
Profit After Tax	11	2	-14	-15	-24	-16	1	-8	2	3
PAT Margin (%)	13.3%	2.9%	-24.8%	-26.9%	-35.0%	-20.2%	0.9%	-14.7%	1.9%	3.7%
Adjusted EPS (₹)	5.4	0.9	-7.1	-7.6	-9.8	-6.3	0.3	-3.3	0.6	1.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Brooks Laboratories - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	122	128	114	100	98	64	65	57	70	115
Share Capital ⓘ	16	16	16	16	25	25	25	25	26	29
Reserves ⓘ	106	112	98	83	74	40	40	32	43	86
Debt +	6	13	25	28	24	8	5	6	5	6
Long Term Debt	0	11	17	14	11	1	0	0	0	0
Short Term Debt	5	2	9	14	13	7	5	6	5	6
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	16	18	27	27	26	13	26	23	15	14
Others Liabilities ⓘ	13	-2	-4	2	9	7	8	7	4	6
Total Liabilities ⓘ	156	158	162	157	158	93	103	92	94	141
Fixed Assets
Net Fixed Assets ⓘ +	16	125	124	117	113	15	15	15	14	14
Gross Block	23	127	132	132	133	20	21	23	23	25
Accumulated Depreciation	7	2	8	15	19	5	6	8	10	11
CWIP ⓘ	87	0	1	0	0	0	1	0	0	0
Investments ⓘ	0	1	1	0	0	47	47	47	47	91
Inventories	7	8	11	10	14	12	17	11	10	9
Trade Receivables	19	11	10	11	16	10	15	13	16	20
Cash Equivalents	2	2	2	3	2	1	1	1	1	1
Others Assets ⓘ	25	12	13	14	14	8	8	5	7	6
Total Assets ⓘ	156	158	162	157	158	93	103	92	94	141

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	8	10	-6	-5	-9	-1	3	1	-10	3
PBT ⓘ	11	2	-18	-15	-14	-8	1	-8	2	3
Adjustment ⓘ	1	3	10	9	12	10	2	3	2	1
Changes in Working Capital ⓘ	2	6	2	1	-8	2	0	6	-13	-3
Tax Paid ⓘ	-5	-2	-1	-1	-0	-4	-0	-0	0	1
Cash Flow From Investing Activity ⓘ +	-14	-17	-5	1	-2	-1	1	-0	0	-45
Capex	-34	-17	-6	1	-2	-1	1	-0	-0	-1
Net Investments	20	0	0	0	-0	0	-0	-0	1	-44
Others ⓘ	1	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	4	7	12	6	10	1	-4	-0	10	42
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	11	43
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-1	-1	-3	-3	-3	-3	-1	-1	-1	-1
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	5	8	14	9	13	4	-4	1	-1	1
Net Cash Flow ⓘ	-1	-0	1	2	-2	-0	0	-0	0	-0

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	9.11	1.33	-11.38	-13.83	-24.62	-19.17	1.03	-13.44	2.42	3.31
ROCE (%)	9.69	2.59	-10.64	-8.6	-7.77	-5.24	1.87	-11.21	3.5	4.35
Asset Turnover Ratio	0.55	0.41	0.36	0.35	0.44	0.62	0.78	0.57	0.85	0.7
PAT to CFO Conversion(x)	0.73	5	N/A	N/A	N/A	N/A	3	N/A	-5	1
Working Capital Days
Receivable Days	87.20	83.30	66.90	71.60	70.70	59.40	58.40	91.30	66.80	80.30
Inventory Days	32.40	40.50	61.30	71.20	62.40	61.80	68.70	91.70	48	41.60
Payable Days	119.80	169.60	208.60	248.90	207.30	150.70	144.90	221.60	125.10	98.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Brooks Laboratories Ltd FAQs

The current trading price of Brooks Laboratories on 04-Jun-2026 16:59 is ₹63.98.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Brooks Laboratories stood at ₹188.5 Cr

The latest P/E ratio of Brooks Laboratories as of 03-Jun-2026 is 32.47.

The latest P/B ratio of Brooks Laboratories as of 03-Jun-2026 is 1.56.

The 52-week high of Brooks Laboratories is ₹165.9 and the 52-week low is ₹36.90.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Brooks Laboratories is ₹85.74 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Brooks Laboratories Ltd is a below average quality company.

The key valuation ratios of Brooks Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Brooks Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Brooks Laboratories Ltd

The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production.

The company has set up a well equipped manufacturing unit at Baddi, Himachal Pradesh in the year 2006 and has been awarded a G.M.P Certification for following Good Manufacturing Practices under â€œRevised Schedule Mâ€ of Drugs & Cosmetics Rules, 1945 in respect of various categories of Tablets, Capsules, Liquid Orals, Dry Syrups, SVP (Liquid & Dry) and Ophthalmic Section by The Health & Family Welfare Department, Himachal.

Companyâ€™s manufacturing facility at Baddi is capable of manufacturing products confirming to TRS 908 of 2003 (WHO GMP) standards. Its Quality Management System at the factory at Baddi is certified as complying to ISO 9001:2008.

Product of the company

The company has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials. These products are manufactured in accordance with highest international standards in facilities as per norms of WHO-GMP & ISO 9000-2008.

Some of the product categories are:

Beta Lactum
Cephalosporins
Carbapenems
General Injectable (Dry Powder)
General Injectable (Liquid)
Cortico Steroids

Brooks Laboratories Ltd (BROOKS)

Brooks Laboratories Ltd (BROOKS)

Brooks Laboratories stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Brooks Laboratories - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Brooks Laboratories Ltd FAQs

About Brooks Laboratories Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Brooks Laboratories Ltd (BROOKS)

Brooks Laboratories Ltd (BROOKS)

Brooks Laboratories stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Brooks Laboratories - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Brooks Laboratories Ltd FAQs

What is the share price of Brooks Laboratories?

What is the market cap of Brooks Laboratories?

What is the P/E ratio of Brooks Laboratories?

What is the P/B ratio of Brooks Laboratories?

What is the 52-week high and low of Brooks Laboratories?

What is the TTM revenue of Brooks Laboratories?

Is Brooks Laboratories Ltd a good quality company?

Is Brooks Laboratories Ltd undervalued or overvalued?

Is Brooks Laboratories Ltd a good buy now?

About Brooks Laboratories Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.